Anagliptin (BioDeep_00000715551)
代谢物信息卡片
Anagliptin
化学式: C19H25N7O2 (383.206963)
中文名称: 阿拉格列汀
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCCC3C#N
InChI: InChI=1S/C19H25N7O2/c1-13-7-16-21-9-14(11-26(16)24-13)18(28)22-12-19(2,3)23-10-17(27)25-6-4-5-15(25)8-20/h7,9,11,15,23H,4-6,10,12H2,1-3H3,(H,22,28)/t15-/m0/s1
描述信息
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor
D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:136043
- KEGGdrug: D09780
- PubChem: 44513473
- DrugBank: DB12417
- ChEMBL: CHEMBL1929396
- ChEMBL: CHEMBL1929387
- CAS: 739366-20-2
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Eri Watanabe, Tsutomu Wada, Akira Okekawa, Fuka Kitamura, Go Komatsu, Yasuhiro Onogi, Seiji Yamamoto, Masakiyo Sasahara, Munehiro Kitada, Daisuke Koya, Hiroshi Tsuneki, Toshiyasu Sasaoka. Stromal cell-derived factor 1 (SDF1) attenuates platelet-derived growth factor-B (PDGF-B)-induced vascular remodeling for adipose tissue expansion in obesity.
Angiogenesis.
2020 11; 23(4):667-684. doi:
10.1007/s10456-020-09738-6. [PMID: 32699964] - Yuriko Sakai, Guanliang Chen, Yinhua Ni, Fen Zhuge, Liang Xu, Naoto Nagata, Shuichi Kaneko, Tsuguhito Ota, Mayumi Nagashimada. DPP-4 Inhibition with Anagliptin Reduces Lipotoxicity-Induced Insulin Resistance and Steatohepatitis in Male Mice.
Endocrinology.
2020 10; 161(10):. doi:
10.1210/endocr/bqaa139. [PMID: 32790863] - Yuji Hotta, Sena Takahashi, Misato Tokoro, Aya Naiki-Ito, Kotomi Maeda, Ryoya Kawata, Tomoya Kataoka, Yuya Ohta, Takashi Hamakawa, Satoru Takahashi, Takahiro Yasui, Kazunori Kimura. Anagliptin, a dipeptidyl peptidase-4 inhibitor, improved bladder function and hemodynamics in rats with bilateral internal iliac artery ligation.
Neurourology and urodynamics.
2020 09; 39(7):1922-1929. doi:
10.1002/nau.24449. [PMID: 32725853] - Masato Furuhashi, Ichiro Sakuma, Takeshi Morimoto, Yukimura Higashiura, Akiko Sakai, Megumi Matsumoto, Mio Sakuma, Michio Shimabukuro, Takashi Nomiyama, Osamu Arasaki, Koichi Node, Shinichiro Ueda. Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.
Cardiovascular diabetology.
2020 06; 19(1):89. doi:
10.1186/s12933-020-01061-0. [PMID: 32539832] - Mitsuhiro Kawakubo, Miyako Tanaka, Kozue Ochi, Akiko Watanabe, Marie Saka-Tanaka, Yohei Kanamori, Naoki Yoshioka, Satoko Yamashita, Moritaka Goto, Michiko Itoh, Ibuki Shirakawa, Sayaka Kanai, Hiromi Suzuki, Makoto Sawada, Ayaka Ito, Masatoshi Ishigami, Mitsuhiro Fujishiro, Hiroshi Arima, Yoshihiro Ogawa, Takayoshi Suganami. Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects.
Scientific reports.
2020 01; 10(1):983. doi:
10.1038/s41598-020-57935-6. [PMID: 31969650] - Takeshi Onoue, Motomitsu Goto, Eri Wada, Mariko Furukawa, Takayuki Okuji, Norio Okada, Tomoko Kobayashi, Shintaro Iwama, Mariko Sugiyama, Taku Tsunekawa, Hiroshi Takagi, Daisuke Hagiwara, Yoshihiro Ito, Yoshiaki Morishita, Yusuke Seino, Hidetaka Suga, Ryoichi Banno, Yoji Hamada, Masahiko Ando, Etsuko Yamamori, Hiroshi Arima. Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial.
PloS one.
2020; 15(1):e0228004. doi:
10.1371/journal.pone.0228004. [PMID: 31990936] - Tomoko Nakagawa, Yoshio Nagai, Yutaro Yamamoto, Atsushi Miyachi, Hitoshi Hamajima, Eri Mieno, Masaki Takahashi, Eisuke Inoue, Yasushi Tanaka. Effects of anagliptin on plasma glucagon levels and gastric emptying in patients with type 2 diabetes: An exploratory randomized controlled trial versus metformin.
Diabetes research and clinical practice.
2019 Dec; 158(?):107892. doi:
10.1016/j.diabres.2019.107892. [PMID: 31669625] - Minglong Xin, Xianglan Jin, Xiangdan Cui, Chunzi Jin, Limei Piao, Ying Wan, Shengnan Xu, Shengming Zhang, Xueling Yue, Hailong Wang, Yongshan Nan, Xianwu Cheng. Dipeptidyl peptidase-4 inhibition prevents vascular aging in mice under chronic stress: Modulation of oxidative stress and inflammation.
Chemico-biological interactions.
2019 Dec; 314(?):108842. doi:
10.1016/j.cbi.2019.108842. [PMID: 31586451] - Atsuko Chihara, Atsushi Tanaka, Takeshi Morimoto, Mio Sakuma, Michio Shimabukuro, Takashi Nomiyama, Osamu Arasaki, Shinichiro Ueda, Koichi Node. Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial.
Cardiovascular diabetology.
2019 11; 18(1):158. doi:
10.1186/s12933-019-0965-3. [PMID: 31733647] - Daisuke Kaya, Kosuke Kaji, Yuki Tsuji, Satoko Yamashita, Koh Kitagawa, Takahiro Ozutsumi, Yukihisa Fujinaga, Hiroaki Takaya, Hideto Kawaratani, Kei Moriya, Tadashi Namisaki, Takemi Akahane, Hitoshi Yoshiji. TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats.
Cells.
2019 09; 8(10):. doi:
10.3390/cells8101153. [PMID: 31561561] - Satoko Yamashita, Yuriko Kawakami, Hiroyuki Sato, Sou Sugitani, Moritaka Goto, Noriaki Kato. Contribution of intestinal dipeptidyl peptidase-4 inhibition for incretin-dependent improved glucose tolerance in mice.
European journal of pharmacology.
2019 Sep; 859(?):172521. doi:
10.1016/j.ejphar.2019.172521. [PMID: 31276666] - Moritaka Goto, Shinji Furuta, Satoko Yamashita, Hiroyuki Hashimoto, Wataru Yano, Noriyuki Inoue, Noriaki Kato, Kohei Kaku. Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport.
Journal of diabetes investigation.
2018 Nov; 9(6):1261-1269. doi:
10.1111/jdi.12860. [PMID: 29754453] - Qi Li, Mingyu Zhang, Lina Xuan, Yanli Liu, Chang Chen. Anagliptin inhibits neointimal hyperplasia after balloon injury via endothelial cell-specific modulation of SOD-1/RhoA/JNK signaling in the arterial wall.
Free radical biology & medicine.
2018 06; 121(?):105-116. doi:
10.1016/j.freeradbiomed.2018.04.580. [PMID: 29715547] - Akira Kurozumi, Yosuke Okada, Tadashi Arao, Takuya Kobayashi, Daisaku Masuda, Shizuya Yamashita, Yoshiya Tanaka. Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients.
Journal of diabetes investigation.
2018 Mar; 9(2):360-365. doi:
10.1111/jdi.12739. [PMID: 28853228] - Qi Li, Xiayang Wu, Yanli Liu, Mingyu Zhang, Xue Bai, Chang Chen. The effect of anagliptin on intimal hyperplasia of rat carotid artery after balloon injury.
Molecular medicine reports.
2017 Dec; 16(6):8003-8010. doi:
10.3892/mmr.2017.7667. [PMID: 28990108] - Akihiko Sato, Satoshi Suzuki, Shunsuke Watanabe, Takeshi Shimizu, Yuichi Nakamura, Tomofumi Misaka, Tetsuro Yokokawa, Tetsuro Shishido, Shu-Ichi Saitoh, Takafumi Ishida, Isao Kubota, Yasuchika Takeishi. DPP4 Inhibition Ameliorates Cardiac Function by Blocking the Cleavage of HMGB1 in Diabetic Mice After Myocardial Infarction.
International heart journal.
2017 Oct; 58(5):778-786. doi:
10.1536/ihj.16-547. [PMID: 28966327] - Wataru Yano, Noriyuki Inoue, Shiori Ito, Takahiro Itou, Misako Yasumura, Yasunobu Yoshinaka, Sumihiko Hagita, Moritaka Goto, Takashi Nakagawa, Keisuke Inoue, Sohei Tanabe, Kohei Kaku. Mechanism of lipid-lowering action of the dipeptidyl peptidase-4 inhibitor, anagliptin, in low-density lipoprotein receptor-deficient mice.
Journal of diabetes investigation.
2017 Mar; 8(2):155-160. doi:
10.1111/jdi.12593. [PMID: 27860391] - Takeshi Osonoi, Miyoko Saito, Natsuyo Hariya, Moritaka Goto, Kazuki Mochizuki. Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.
Peptides.
2016 12; 86(?):118-125. doi:
10.1016/j.peptides.2016.10.011. [PMID: 27780736] - Tsutomu Hirano, Satoko Yamashita, Masaki Takahashi, Hiroyuki Hashimoto, Yusaku Mori, Moritaka Goto. Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits.
Metabolism: clinical and experimental.
2016 06; 65(6):893-903. doi:
10.1016/j.metabol.2016.03.010. [PMID: 27173468] - Nobuhiro Tahara, Sho-Ichi Yamagishi, Munehisa Bekki, Norihiro Kodama, Tomohisa Nakamura, Yoichi Sugiyama, Tamami Oshige, Yuki Kumashiro, Akihiro Honda, Atsuko Tahara, Sachiyo Igata, Yoshihiro Fukumoto. Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients.
Current vascular pharmacology.
2016; 14(6):552-562. doi:
10.2174/1570161114666160625090212. [PMID: 27357182] - Yoshiki Higashijima, Tetsuhiro Tanaka, Junna Yamaguchi, Shinji Tanaka, Masaomi Nangaku. Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury.
American journal of physiology. Renal physiology.
2015 Apr; 308(8):F878-87. doi:
10.1152/ajprenal.00590.2014. [PMID: 25656369] - Hirokazu Kakuda, Junji Kobayashi, Masahiro Kakuda, Junichi Yamakawa, Noboru Takekoshi. The effect of anagliptin treatment on glucose metabolism and lipid metabolism, and oxidative stress in fasting and postprandial states using a test meal in Japanese men with type 2 diabetes.
Endocrine.
2015 Apr; 48(3):1005-9. doi:
10.1007/s12020-014-0376-x. [PMID: 25115636] - Miyako Kishimoto, Mitsuhiko Noda. Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.
Clinical drug investigation.
2015 Feb; 35(2):141-7. doi:
10.1007/s40261-014-0260-8. [PMID: 25511640] - Kazutaka Aoki, Takahiro Ijima, Hiroshi Kamiyama, Kazunari Kamiko, Yasuo Terauchi. Anagliptin decreases serum lathosterol level in patients with type 2 diabetes: a pilot study.
Expert opinion on pharmacotherapy.
2015; 16(12):1749-54. doi:
10.1517/14656566.2015.1057120. [PMID: 26098722] - Hae Kyung Yang, Kyung Wan Min, Sung Woo Park, Choon Hee Chung, Kyong Soo Park, Sung Hee Choi, Ki-Ho Song, Doo-Man Kim, Moon-Kyu Lee, Yeon-Ah Sung, Sei Hyun Baik, In Joo Kim, Bong-Soo Cha, Jeong Hyun Park, Yu Bae Ahn, In-Kyu Lee, Soon Jib Yoo, Jaetaek Kim, Ie Byung Park, Tae Sun Park, Kun-Ho Yoon. A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes.
Endocrine journal.
2015; 62(5):449-62. doi:
10.1507/endocrj.ej14-0544. [PMID: 25819061] - Shinya Nishio, Mariko Abe, Hiroyuki Ito. Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability.
Diabetes, metabolic syndrome and obesity : targets and therapy.
2015; 8(?):163-71. doi:
10.2147/dmso.s54679. [PMID: 25834461] - S Furuta, M Goto, M Tamura, S Yamashita, K Nakaya, Y Furuta. The relationship between anagliptin concentration showing over 80\% inhibition of plasma dipeptidyl peptidase-4 activity and its protective effect against glucagon-like peptide-1 degradation.
Drug research.
2014 Mar; 64(3):130-5. doi:
10.1055/s-0033-1353185. [PMID: 23965798] - Keizo Nakaya, Naoto Kubota, Iseki Takamoto, Tetsuya Kubota, Hisayuki Katsuyama, Hiroyuki Sato, Kumpei Tokuyama, Shinji Hashimoto, Moritaka Goto, Takahito Jomori, Kohjiro Ueki, Takashi Kadowaki. Dipeptidyl peptidase-4 inhibitor anagliptin ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet.
Metabolism: clinical and experimental.
2013 Jul; 62(7):939-51. doi:
10.1016/j.metabol.2013.01.010. [PMID: 23790528] - Shinji Furuta, Miyuki Tamura, Hiroko Hirooka, Yukie Mizuno, Mika Miyoshi, Yoshiyuki Furuta. Pharmacokinetic disposition of anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in rats and dogs.
European journal of drug metabolism and pharmacokinetics.
2013 Jun; 38(2):87-96. doi:
10.1007/s13318-013-0119-z. [PMID: 23436178] - Shinji Furuta, Clair Smart, Andrew Hackett, Rajdeep Benning, Steve Warrington. Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans.
Xenobiotica; the fate of foreign compounds in biological systems.
2013 May; 43(5):432-42. doi:
10.3109/00498254.2012.731618. [PMID: 23075005]